Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on LifeMD (NASDAQ:LFMD) and maintained a $15 price target.
September 20, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Sarah James has reiterated an Overweight rating for LifeMD, maintaining a $15 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $15 price target by a reputable analyst suggests a positive outlook for LifeMD. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100